Orticumab

DB16653InvestigationalProtein Based Therapies

Orticumab is under investigation in clinical trial NCT04776629 (A Proof-of-activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors).

Mechanism: Pharmacologically active on Apolipoprotein B-100
Curator reviewed
Code names: BI-204 · MLDL-1278A · RG-7418

Resolves to

Compound

UNII2O892R8U24CAS1314241-10-5

Targets

P04114APOB

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Orticumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account